מדינה: ניו זילנד
שפה: אנגלית
מקור: Medsafe (Medicines Safety Authority)
Infliximab 100mg;
Janssen-Cilag (New Zealand) Ltd
Infliximab 100 mg
100 mg
Powder for injection
Active: Infliximab 100mg Excipient: Dibasic sodium phosphate dihydrate Monobasic sodium phosphate monohydrate Polysorbate 80 Sucrose
Vial, glass, 100 mg
Prescription
Prescription
Janssen Biotech Inc
Rheumatoid Arthritis REMICADE is a ?Disease-Controlling Anti-Rheumatic Therapy" (DCART) indicated for: · the reduction of signs and symptoms · prevention of structural joint damage (erosions and joint space narrowing) · improvement in physical function in patients with active disease. Remicade should be given in combination with methotrexate.
Package - Contents - Shelf Life: Vial, glass, - 100 mg - 36 months from date of manufacture stored at 2° to 8°C (Refrigerate) 12 months not refrigerated stored at or below 30°C. Single period. Do not return to refrigerator.
1999-03-10
REMICADE ® (220531) ACMI NZ REMICADE ® _Infliximab _ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about REMICADE. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you using REMICADE against the benefits it is expected to have for you. IF YOU HAVE ANY CONCERNS ABOUT BEING GIVEN THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET. You may need to read it again. WHAT REMICADE IS USED FOR REMICADE contains the active ingredient, infliximab. Infliximab is a monoclonal antibody that is produced from human and mouse proteins by recombinant technology. Monoclonal antibodies are proteins that recognise and bind to certain special proteins in the body. Infliximab acts by binding to a special protein in the body called called tumour necrosis factor alpha (TNF α ). In people with diseases such as Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and psoriasis, the body produces too much TNF α , which can cause the body’s immune system to attack normal healthy parts of the body. REMICADE can block the damage caused by too much TNF α . RHEUMATOID ARTHRITIS Rheumatoid arthritis is an inflammatory disease of the joints. REMICADE is used to reduce the signs and symptoms of rheumatoid arthritis and to prevent damage to the joints. You will also be given a disease-modifying medicine called methotrexate. ANKYLOSING SPONDYLITIS Ankylosing spondylitis is an inflammatory disease of the spine. REMICADE can reduce the signs and symptoms of ankylosing spondylitis, thereby improving physical function. PSORIATIC ARTHRITIS Psoriatic arthritis is an inflammatory disease of the joints in which psoriasis usually occurs in association with arthritis. Often the fingers and toes are affected, although it may occur in other parts of the body. REMICADE is used to reduce the signs and קרא את המסמך השלם
22.230811 1 REMICADE (240207) ADS REMICADE ® POWDER FOR INJECTION INFLIXIMAB NEW ZEALAND DATA SHEET 1. PRODUCT NAME REMICADE 100 mg POWDER FOR INJECTION 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial of the REMICADE product contains infliximab 100 mg. Infliximab is a chimeric human-murine IgG1 monoclonal antibody produced in murine hybridoma cells by recombinant DNA technology. After reconstitution each mL contains 10 mg of infliximab. For a full list of excipients, see SECTION 6.1. 3. PHARMACEUTICAL FORM Powder for injection REMICADE Powder for Injection is to be reconstituted with 10 mL sterile Water for Injections and further diluted in 0.9% sodium chloride solution for infusion. REMICADE is supplied as a white lyophilised powder in individually-boxed single-use glass vials with rubber stoppers and aluminium crimps protected by plastic caps. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS REMICADE is indicated for: RHEUMATOID ARTHRITIS REMICADE is a “Disease-Controlling Anti-Rheumatic Therapy” (DCART) indicated for: • the reduction of signs and symptoms • prevention of structural joint damage (erosions and joint space narrowing) • improvement in physical function in patients with active disease. REMICADE should be given in combination with methotrexate. 22.230811 2 REMICADE (240207) ADS ANKYLOSING SPONDYLITIS REMICADE is indicated for the reduction of signs and symptoms and improvement in physical function in patients with active disease. PSORIATIC ARTHRITIS REMICADE is indicated for: • the reduction of signs and symptoms of arthritis • improvement in physical function • reduction in psoriasis as measured by PASI (an index which combines symptom evaluation and body surface area) • prevention of worsening of disability • inhibition of the progression of structural damage of active arthritis, as measured by x- ray in patients with active and progressive psoriatic arthritis. REMICADE should be administered • In combination with methotrexate, or • Alone in patients w קרא את המסמך השלם